ANI Pharmaceuticals
ANIP
72 hedge funds and large institutions have $128M invested in ANI Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 32 increasing their positions, 20 reducing their positions, and 15 closing their positions.
60% more repeat investments, than reductions
Existing positions increased: 32 | Existing positions reduced: 20
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
11% less funds holding
Funds holding: 81 → 72 (-9)
18% less capital invested
Capital invested by funds: $156M → $128M (-$27.8M)
60% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 15
Top Buyers
Top Sellers
| 1 |
Millennium Management
New York
|
-$7.79M |
| 2 |
LOAMU
Lombard Odier Asset Management (USA)
New York
|
-$5.17M |
| 3 |
EI
EAM Investors
Solana Beach,
California
|
-$3.03M |
| 4 |
Morgan Stanley
New York
|
-$3.01M |
| 5 |
Renaissance Technologies
New York
|
-$2.68M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
D.E. Shaw & Co
New York
| – | -$449K | -13,039 | Closed |
|
77
SG Americas Securities
New York
| – | -$375K | -10,883 | Closed |
|
|
STC
78
SEI Trust Company
Oaks,
Pennsylvania
| – | -$351K | -10,180 | Closed |
|
79
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$267K | -7,759 | Closed |
|
|
SIM
80
Spark Investment Management
New York
| – | -$206K | -6,000 | Closed |
|
|
TRCT
81
Tower Research Capital (TRC)
New York
| – | -$183K | -5,313 | Closed |
|
82
US Bancorp
Minneapolis,
Minnesota
| – | -$173K | -5,023 | Closed |
|
|
SGAM
83
Smith Group Asset Management
Dallas,
Texas
| – | -$35K | -1,020 | Closed |
|
|
VFA
84
Virtus Fund Advisers
Hartford,
Connecticut
| – | -$20K | -586 | Closed |
|
|
LTFS
85
Ladenburg Thalmann Financial Services
Miami,
Florida
| – | -$9K | -250 | Closed |
|
ANIP Hedge Fund Activity: Q3 2014 in Review
72 of the 3,446 institutional investors tracked by Wall St. Rank reported a position in ANI Pharmaceuticals (ANIP) for Q3 2014, worth a combined $128M — down 18% from $156M a quarter earlier.
Sellers outnumbered buyers: 15 funds closed out of ANIP and 6 opened new positions — a net loss of 9 holders — while 20 trimmed existing stakes and 32 added.
The largest buyer was Consonance Capital Management, adding an estimated $5.83M. The largest seller was Millennium Management, cutting an estimated $7.79M.
- 72 institutional investors held ANI Pharmaceuticals (ANIP) as of Q3 2014, down from 81 in Q2 2014.
- Funds reported $128M of ANI Pharmaceuticals stock for Q3 2014, down 18% quarter-over-quarter.
- 6 funds opened new ANI Pharmaceuticals positions in Q3 2014 and 15 closed out, a net change of -9 holders.
- The largest ANI Pharmaceuticals buyer in Q3 2014 was Consonance Capital Management, an estimated $5.83M added.
- The largest ANI Pharmaceuticals seller in Q3 2014 was Millennium Management, an estimated $7.79M sold.
Based on aggregated 13F filings for Q3 2014.